Business Wire

DIXA

10.3.2022 11:32:05 CET | Business Wire | Press release

Share
Dixa Leverages $43 Million Double Acquisition of CX Intelligence and Automation Pioneers, Miuros and Solvemate, to Deliver High-value Customer Experiences at Scale

Danish customer support innovator Dixa has today announced the acquisitions of analytics leader Miuros , and automation pioneer Solvemate . Driven by a need amongst service teams to connect to customers with intelligence, empathy, and the right information, the double acquisition is valued at $43 million and strengthens Dixa’s long-term vision to set a new standard in experience and data-driven conversational customer service, giving brands the toolkit they need to utilize data on a new scale for automation, measurement and analytics.

Dixa is used by consumer-facing and digital-first brands to serve customers across multiple channels, touchpoints and experiences from a single screen including social media, chat, voice and messaging apps, enabling an outstanding experience for both customers and agents. With cross-channel prioritization features, powerful routing capabilities, and flexible integrations, Dixa helps brands across the globe deliver value-driven customer experiences at scale, all from a single platform.

Solvemate builds in a powerful self-service layer into the platform that ensures brands can create a painless customer experience with the power of AI to give instant, personal, reliable answers via any customer-facing channel, or funnel requests to the right agent. Its introduction means users can now handle the end-to-end customer journey in a more intelligent, automated and conversational way, while also improving the agent experience through more seamless bot-to-agent handovers.

Miuros was designed to help brands turn customer data into actionable insights with AI-powered analytics, quality assurance and automation. Its addition to the Dixa platform will allow service leaders to harness the power of this technology and gain a better, more comprehensive understanding of the service function. Underpinned by Dixa’s data-rich foundation, service leaders will be able to make stronger, data-informed decisions, such as spotting and acting upon trends in agent productivity and sentiment.

“To create value-driven experiences, brands need a complete platform that leverages data, AI and machine learning to deliver the right knowledge to customers, support agents and internal teams at the right time,” said Mads Fosselius, CEO and co-founder of Dixa. “In being able to draw on our data-rich foundation and existing knowledge base, Elevio, the addition of Miuros and Solvemate will allow service leaders to leverage data on a new scale for automation, measurement and insights from a single platform, setting an entirely new standard in data-driven customer service.”

Dixa’s acquisition rounds out an impressive service offering that also includes a new, bespoke messaging product that delivers rich messaging across web, mobile, and app environments. Dixa Messenger will launch in March 2022, joining native telephony, email, and social messaging support on Dixa’s platform.

“Dixa Messenger is a powerful new service desk for your brand, allowing customer loving teams to create great experiences wherever your customers are,” says Rob Krassowski, Dixa’s VP of Product, “Solvemate and Miuros allow us to take a more data-driven approach to automation and self-service, plus give service agents the tools that they need to create compelling experiences for customers and real business value for their brands.”

Erik Pfannmöller, CEO & Co-founder from Solvemate added: “Powered by smart conversational AI, Solvemate allows brands to create highly personalized chatbot conversations at scale, guiding customers to find answers when they need them. Reducing the number of common, repetitive requests handled by agents means that service teams can focus their expertise where it matters most: solving the more complex cases which require a human touch. By giving consumers faster solutions and taking away noise for agents, we share Dixa’s ambition to service a multiexperience world for delivering unparalleled customer service.”

Benoit Gagnon, CEO & Co-founder from Miuros said: “Dixa is the only platform that can turn a traditional customer service organization into a value creation team by elevating both the agent and customer experience, and we’re delighted to be joining during such an exciting period. Miuros was designed to bring customer service data to life, creating actionable insights to streamline operations, as well as empowering the whole company to create an outstanding customer experience. By adding Miuros’ analytics capabilities, service leaders will now be able to optimize their operations through AI and obtain actionable insights, without needing to stitch together multiple siloed solutions.”

Solvemate, with a global customer base of over 100 brands such as On, JustPark, Sport24, Holidu and CreditPlus, was founded in 2015 by co-founders Erik Pfannmöller, Jürgen Vogel and Christian Blomberg. Miuros, with a global customer base of over 100 mid-market and enterprise brands, including Deezer, Wise, About You, Freenow and Swapfiets, was founded in 2016 by co-founders Benoit Gagnon, Dr. Ricardo De Aldama and Daniele Alfarone. Solvemate and Miuros will continue to service their current customers across platforms in addition to expanding on existing integrations with Dixa.

Dixa has raised $155 million in funding to date with backing from Notion Capital, Project A Ventures, SEED Capital and recently from General Atlantic. The company has offices in Copenhagen, London, Berlin, Paris, Chicago, Tallinn, Kiev, Tel Aviv and Melbourne.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye